TITLE

Influence of preferred foodstuffs on the antinociceptive effects of orally administered buprenorphine in laboratory rats

AUTHOR(S)
Leach, Matthew C.; Forrester, Alison R.; Flecknell, Paul A.
PUB. DATE
January 2010
SOURCE
Laboratory Animals;Jan2010, Vol. 44 Issue 1, p54
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Oral administration of buprenorphine is becoming a popular method of providing analgesia for laboratory rodents. The mixing of buprenorphine with flavoured jello, which rodents find palatable, is becoming a commonly used method as it is thought to improve the efficacy of oral buprenorphine by increasing the time available for it to be absorbed via the oral mucosa. The aim of this study was to assess the effect of various methods of buprenorphine administration (subcutaneous saline, subcutaneous buprenorphine [0.05 mg/kg], buprenorphine gavage [0.5 mg/kg], buprenorphine in jello [0.5 mg/kg] and buprenorphine in golden syrup [0.5 mg/kg]) on thermal antinociceptive thresholds in laboratory rats. Buprenorphine administered subcutaneously, by gavage, in jello and in syrup induced significant increases in thermal antinociceptive thresholds compared with saline. This effect was observed up to 5 h postadministration for buprenorphine administered subcutaneously and by gavage, but only for one hour postadministration for buprenorphine administered in jello and in syrup.
ACCESSION #
48415840

 

Related Articles

  • More precise and effective antibiotic use.  // Consumers' Research Magazine;Sep97, Vol. 80 Issue 9, p40 

    Focuses on the method of `carbon-baiting' technology used in the antibiotic administration. Significance of the technology; How Doctor Robert Ollar, a microbiologist describes the method

  • Comparison of the antiemetics metoclopramide and promethazine in labour. Vella, Louise; Francis, Deborah; Houlton, Peter; Reynolds, Felicity // British Medical Journal (Clinical Research Edition);4/20/1985, Vol. 290 Issue 6476, p1173 

    Focuses on antiemetics metoclopramide and promethazine in labor. Use of placebo in the study; Discussions on the difference in the group; Significance of analgesia after metoclopramide.

  • If a Drug Is New, Does That Make It Better?  // Health Letter;Jan2011, Vol. 27 Issue 1, p9 

    The article focuses on the legislative test of drug effectiveness to gain approval from the U.S. Food and Drug Administration.

  • An early request for medication. Stokell, Richard // Pulse;4/5/2004, Vol. 64 Issue 14, p78 

    Presents a case of a 44-year-old patient with chronic anxiety and low back pain. Details on the medication of the patient; Efficacy of prescribing diazepam and dihydrocodeine drugs; Provision of analgesia to painful long-term conditions. INSET: Key points.

  • Methodology of monitored release of a new preparation: buprenorphine. Harcus, A.W.; Ward, A.E.; Smith, D.W. // British Medical Journal;7/21/1979, Vol. 2 Issue 6183, p163 

    Analyzes the administration of buprenorphine in Great Britain. Assessment of analgesic efficacy after administration; Observation of systolic and diastolic pressures and pulse rates; Absence of adverse effects attributable to buprenorphine.

  • PROLONGED REGIONAL ANALGESIA WITH MORPHINE--EPIDURALLY. Schwarz, Thom // RN;May82, Vol. 45 Issue 5, p33 

    Presents clinical tests on morphine sulfate (MS) given epidurally without respiratory depression. Details on the complete epidural MS analgesia; Risks involved in epidural analgesia; Results of tests of MS with terminal cancer patients. INSETS: EPIDURAL ANALGESIA; WHAT TO CHECK WHEN THE AGENT...

  • CuraGen receives FDA approval for clinical trials.  // Fairfield County Business Journal;3/17/2003, Vol. 42 Issue 11, p17 

    Announces the U.S. Food and Drug Administration's approval of CuraGen Corp.'s investigational new drug application to initiate clinical trials for CG53135 for the treatment of oral mucositis. Results of preclinical studies of the protein.

  • Decisions Update.  // PharmaWatch: Biotechnology;Nov2006, Vol. 5 Issue 11, p9 

    The article focuses on several decisions taken by the U.S. Food and Drug Administration (FDA) regarding various drugs. The FDA has asked MGI Pharma to conduct an additional phase III trial to support the application to market the treatment of oral mucositis, Saforis. Allos Therapeutics'...

  • Optimum Topical Delivery of Adrenergic Agonists to Oral Mucosa Vasculature. Soref, Cheryl; Fahl, William // Pharmaceutical Research;Feb2015, Vol. 32 Issue 2, p492 

    Purpose: Identify an orotopical vehicle to deliver an α-adrenergic vasoconstrictor to submucosal vasculature that is readily palatable to cancer/bone marrow transplant patients that suppresses chemo-radiotherapy-associated oral mucositis. Methods: A [H] norepinephrine ligand binding assay was...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics